It is not difficult to conclude that the exploration of CDK4/6 inhibitors in other cancers except breast cancer, such as liposarcoma, lymphoma melanoma, and many other advanced cancers [47–50], is still at an early stage and is mostly limited to basic experiments and stage I or II clinical trials (See Table 2). This evidence concerns the gene CDK4 and breast carcinoma.